These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36047214)

  • 1. [Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine].
    Nakai M; Kikkawa A; Funahara H; Matsumoto S; Hiraki K
    Yakugaku Zasshi; 2022; 142(9):1021-1029. PubMed ID: 36047214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04).
    Shimoyama R; Imamura Y; Uryu K; Mase T; Taguri M; Okuda T; Fujimura Y; Hayashi M; Tanaka S; Sawamukai K; Minami H
    Jpn J Clin Oncol; 2024 Jan; 54(1):70-80. PubMed ID: 37801431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
    Ogul A; Kidi MM; Buyuksimsek M
    J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
    Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
    Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.
    Kurihara T; Kogo M; Ishii M; Yoneyama K; Kitamura K; Shimada K; Shimizu S; Yoshida H; Kiuchi Y
    Hepatogastroenterology; 2015; 62(138):478-84. PubMed ID: 25916086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
    Sasaki T; Isayama H; Nakai Y; Togawa O; Kogure H; Ito Y; Yamamoto K; Mizuno S; Yagioka H; Yashima Y; Kawakubo K; Arizumi T; Matsubara S; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):847-53. PubMed ID: 20563811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.
    Kobayashi S; Ueno M; Sugimori K; Morizane C; Kojima Y; Irie K; Goda Y; Morimoto M; Ohkawa S
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1189-1196. PubMed ID: 29071413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
    Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
    World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
    Katayose Y; Ohtsuka H; Kitamura Y; Masuda K; Nakagawa K; Yamamoto K; Yoshida H; Onogawa T; Motoi F; Naitoh T; Rikiyama T; Egawa S; Unno M
    Hepatogastroenterology; 2012 May; 59(115):691-5. PubMed ID: 22469710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
    Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
    Sasaki T; Isayama H; Nakai Y; Ito Y; Yasuda I; Toda N; Yagioka H; Matsubara S; Hanada K; Maguchi H; Kamada H; Hasebe O; Mukai T; Okabe Y; Maetani I; Koike K
    World J Gastroenterol; 2014 Dec; 20(48):18452-7. PubMed ID: 25561816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
    Kobayashi S; Nagano H; Tomokuni A; Gotoh K; Sakai D; Hatano E; Seo S; Terajima H; Uchida Y; Ajiki T; Satake H; Kamei K; Tohyama T; Hirose T; Ikai I; Morita S; Ioka T;
    Ann Surg; 2019 Aug; 270(2):230-237. PubMed ID: 30339627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
    Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
    Ishiwatari H; Hayashi T; Yoshida M; Ono M; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):805-12. PubMed ID: 25687990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
    Yonemoto N; Furuse J; Okusaka T; Yamao K; Funakoshi A; Ohkawa S; Boku N; Tanaka K; Nagase M; Saisho H; Sato T
    Jpn J Clin Oncol; 2007 Nov; 37(11):843-51. PubMed ID: 17942578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen.
    Buyuksimsek M; Kidi MM; Ogul A; Mirili C; Paydas S
    J Gastrointest Cancer; 2021 Mar; 52(1):249-255. PubMed ID: 32185743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
    Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
    Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Sakai D; Kodama Y; Ajiki T; Nagano H; Ioka T
    Cancer Chemother Pharmacol; 2012 May; 69(5):1181-8. PubMed ID: 22237958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.